Publications
207
Citations
1,403
Est. group size
~45
Recurring co-author estimate
Active years
50
Publishing since 1977
Laura Chambers studies cancers of the female reproductive system, especially ovarian, endometrial, and cervical cancer, with a focus on surgical treatment, drug therapies, and patient outcomes. Her work includes clinical studies on chemotherapy regimens, surgical approaches like cytoreductive surgery and HIPEC (a heated chemotherapy treatment delivered directly into the abdomen), genomic profiling of tumors, and factors such as patient frailty, kidney disease, and gut microbiota that affect treatment response. Much of the research involves large clinical databases and multi-institutional collaborations aimed at improving treatment decisions and survival outcomes.
Publication output has grown substantially over the past decade, rising from single digits in 2017-2018 to a sustained high output of roughly 40 papers per year by 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- All welcome: Age and frailty do not impact mirvetuximab safety or efficacy
Gynecologic Oncology · 2026
- Aspirin use and survival outcomes in endometrial cancer.
Journal of Clinical Oncology · 2026
- Effect of statin use on survival in patients with endometrial cancer.
Journal of Clinical Oncology · 2026
- Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma
International Journal of Gynecological Cancer · 2025
- Abstract 5360: Comprehensive analysis of breast cancer genomic alterations across diverse populations using a large real-world database
Cancer Research · 2025
- Abstract 3396: Genomic landscape and ancestry-associated variations of gynecological cancers
Cancer Research · 2025
- PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
International Journal of Gynecological Cancer · 2025
- Supplementary Data from Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer
2025
- 66MO Comprehensive analysis of genomic alterations in breast cancer (BC) across diverse populations using a large real-world database
Annals of Oncology · 2025
- 643P Genomic landscapes of gynecological cancers
Annals of Oncology · 2025
- The modified 5-factor frailty index predicts postoperative outcomes in patients with ovarian cancer undergoing hyperthermic intraperitoneal chemotherapy
Surgical Oncology · 2024
- Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial
Gynecologic Oncology · 2024
- Feasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease
International Journal of Gynecological Cancer · 2024
- Higher incidence of venous thromboembolism associated with increasing lines of treatment in heavily treated ovarian cancer patients
International Journal of Gynecological Cancer · 2024
- Abstract B090: Gut microbial suppression of epithelial ovarian cancer and attenuation of chemoresistance: opportunity for probiotics in patient care to improve survival
Cancer Research · 2024
- Gynecologic Oncology×100
- International Journal of Gynecological Cancer×16
- Gynecologic Oncology Reports×12
- Journal of Clinical Oncology×7
- Cancer Research×6
- Larry J. Copeland
Medicine · The Ohio State University
- Molly Morton
Medicine · The Ohio State University
- Monica Levine
Medicine · The Ohio State University
- David M. O’Malley
Medicine · The Ohio State University
- D. E. Cohn
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile